{"disease":{"id":"urothelial-neoplasm","name":"urothelial neoplasm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06167356","title":"Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06026189","title":"Safely Reduce Cystoscopic Evaluations for Hematuria Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04923178","title":"A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05845814","title":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":390,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03288545","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":348,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04129606","title":"Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Abdelwahab Hashem","has_results":false},{"nct_id":"NCT03219333","title":"A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT06863844","title":"The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor","phase":"","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT02393248","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":201,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04770974","title":"Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University of Florence","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02496208","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03138824","title":"Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT04235777","title":"Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07067749","title":"Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"University of Rome Tor Vergata","has_results":false},{"nct_id":"NCT04200963","title":"A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT07234968","title":"Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT01688999","title":"Cabozantinib for Advanced Urothelial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06630416","title":"Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT06528483","title":"Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":63,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05030077","title":"Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02769962","title":"Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03636256","title":"Evaluation of NanoDoce® in Participants With Urothelial Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"NanOlogy, LLC","has_results":true},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04940299","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06551896","title":"Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03473730","title":"Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03582475","title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT02788201","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":36},"guidelines":[],"source":"Drug Landscape verified database"}